We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Sponsor content
46 result(s) found, displaying 1 to 10
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ABILIFY ASIMTUFII aripiprazole (as monohydrate) 960 mg/3.2 mL prolonged release suspension for injection pre-filled syringe.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ABILIFY ASIMTUFII aripiprazole (as monohydrate) 720 mg/2.4 mL prolonged release suspension for injection pre-filled syringe.
-
Prescription medicine registrationActive ingredients: brexpiprazole.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for VYEPTI eptinezumab 100 mg/mL concentrated injection single use vial.
-
Australian public assessment report (AusPar)New AusPAR for Vyepti (eptinezumab) for the preventive treatment of migraine in adults.
-
Prescription medicine registrationActive ingredients: eptinezumab.
-
Australian public assessment report (AusPar)Australian Public Assessment Report for Brexpiprazole
-
Section 14, TGO91 consentProduct(s) approved for Supply with noncompliant labelling.
-
Section 14, TGO91 consentProduct(s) approved for Supply with noncompliant labelling.
-
Section 14, TGO91 consentProduct(s) approved for Supply with noncompliant labelling.